AggregoTV - AML

AggregoTV - AML

High Dose Therapy and Autologous Stem Cell Transplantation
red blood cells

Discussion on high dose therapy and autologous stem cell transplantation.

Understanding Risk in AML: How Molecular Testing Affects Treatment Options

How does molecular testing impact AML treatment options? Dr. Pinkal Desai discusses molecular testing and how results may help determine the best treatment path for patients.

What Are the Goals of AML Treatment?

Dr. Pinkal Desai defines the role of remission and the specific goals of treatment for AML patients.


An update on the NCRI AML20 trial

Charles Craddock describes the three main questions the trial aims to address, including whether the addition of venetoclax can improve the activity of CPX-351 in adults with AML.

What is new in targeted therapies for AML?

Dr. Navel Daver discusses the use of single agents, such as the FLT3 inhibitor, gilteritinib, and the IDH1 inhibitor, ivosidenib, as well as the outcomes of more recent combination treatments with

Choosing an AML Treatment Path: What Should You Consider?

What should be considered when choosing an AML treatment path? Dr. Pinkal Desai explains the factors that are considered to determine the best treatment for an individual patient.

Is HSCT an option for refractory AML?

During the 3rd Annual Meeting of the IACH, the AML Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR.

Treating older patients with AML in 2020: What is new and promising?

During the 25th Congress of the EHA, the AML Hub spoke to Courtney DiNardo, MD Anderson Cancer Center, Houston, US, about the treatment of elderly patients with AML in 2020.

Challenges in MRD measurement by multiparameter flow cytometry in AML

Professor Jacqueline Cloos, Amsterdam University Medical Center, Amsterdam, NL, presented the topic ‘Challenges in MRD measurement by multiparameter flow cytometry in AML.’

How should sequential therapy be performed in patients with AML?

During the 46th Annual Meeting of the EBMT, the AML Hub spoke to Rémy Duléry, Hôpital Saint-Antoine, Paris, FR, about sequential therapy in patients with relapsed/refractory AML.

ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) In Older Adults


The ASH Clinical Practice Guidelines for Acute Myeloid Leukemia covers the treatment of acute myeloid leukemia in older adults.

David Steensma: Examining H3B-8800 for Myeloid Neoplasms

Dr. David Steensma discusses the results and unanswered questions raised by the first-in-human trial of the splicing modulator in patients with AML, CML...


Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

Combining MBG453 with hypomethylating agents was "extremely well tolerated," with no high-grade immune-related toxicities. Dr. Uma Borate discusses the safety and preliminary efficacy data.


source list reference